메뉴 건너뛰기




Volumn 130, Issue 2, 2013, Pages 269-274

Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC Clinical Trials Group (NCIC CTG IND 199)

Author keywords

Cervical cancer systemic therapy Temsirolimus Phase II trial mTOR pathway

Indexed keywords

PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; TEMSIROLIMUS;

EID: 84880289115     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2013.05.008     Document Type: Article
Times cited : (87)

References (28)
  • 2
    • 0029044886 scopus 로고
    • Prognostic factors in patients with cervix cancer treated by radiation therapy: Results of a multiple regression analysis
    • A.W. Fyles, M. Pintilie, P. Kirkbride, W. Levin, L.A. Manchul, and G.A. Rawlings Prognostic factors in patients with cervix cancer treated by radiation therapy: results of a multiple regression analysis Radiother Oncol 35 2 May 1995 107 117
    • (1995) Radiother Oncol , vol.35 , Issue.2 , pp. 107-117
    • Fyles, A.W.1    Pintilie, M.2    Kirkbride, P.3    Levin, W.4    Manchul, L.A.5    Rawlings, G.A.6
  • 3
    • 23044495279 scopus 로고    scopus 로고
    • Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: A Gynecologic Oncology Group study
    • H.J. Long 3rd, B.N. Bundy, E.C. Grendys Jr., J.A. Benda, D.S. McMeekin, and J. Sorosky Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group study J Clin Oncol 23 21 Jul 20 2005 4626 4633
    • (2005) J Clin Oncol , vol.23 , Issue.21 , pp. 4626-4633
    • Long III, H.J.1    Bundy, B.N.2    Grendys, Jr.E.C.3    Benda, J.A.4    McMeekin, D.S.5    Sorosky, J.6
  • 4
    • 4143135504 scopus 로고    scopus 로고
    • Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study
    • D.H. Moore, J.A. Blessing, R.P. McQuellon, H.T. Thaler, D. Cella, and J. Benda Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study J Clin Oncol 22 15 Aug 1 2004 3113 3119
    • (2004) J Clin Oncol , vol.22 , Issue.15 , pp. 3113-3119
    • Moore, D.H.1    Blessing, J.A.2    McQuellon, R.P.3    Thaler, H.T.4    Cella, D.5    Benda, J.6
  • 5
    • 70350433286 scopus 로고    scopus 로고
    • Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: A Gynecologic Oncology Group study
    • B.J. Monk, M.W. Sill, D.S. McMeekin, D.E. Cohn, L.M. Ramondetta, and C.H. Boardman Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study J Clin Oncol 27 28 Oct 1 2009 4649 4655
    • (2009) J Clin Oncol , vol.27 , Issue.28 , pp. 4649-4655
    • Monk, B.J.1    Sill, M.W.2    McMeekin, D.S.3    Cohn, D.E.4    Ramondetta, L.M.5    Boardman, C.H.6
  • 6
    • 47849125855 scopus 로고    scopus 로고
    • Elevated phosphatidylinositol 3-kinase activation and its clinicopathological significance in cervical cancer
    • X.Y. Zhang, H.Y. Zhang, P.N. Zhang, X. Lu, and H. Sun Elevated phosphatidylinositol 3-kinase activation and its clinicopathological significance in cervical cancer Eur J Obstet Gynecol Reprod Biol 139 2 Aug 2008 237 244
    • (2008) Eur J Obstet Gynecol Reprod Biol , vol.139 , Issue.2 , pp. 237-244
    • Zhang, X.Y.1    Zhang, H.Y.2    Zhang, P.N.3    Lu, X.4    Sun, H.5
  • 7
    • 67149137763 scopus 로고    scopus 로고
    • Morphoproteomic evidence of constitutively activated and overexpressed mTOR pathway in cervical squamous carcinoma and high grade squamous intraepithelial lesions
    • W. Feng, X. Duan, J. Liu, J. Xiao, and R.E. Brown Morphoproteomic evidence of constitutively activated and overexpressed mTOR pathway in cervical squamous carcinoma and high grade squamous intraepithelial lesions Int J Clin Exp Pathol 2 3 2009 249 260
    • (2009) Int J Clin Exp Pathol , vol.2 , Issue.3 , pp. 249-260
    • Feng, W.1    Duan, X.2    Liu, J.3    Xiao, J.4    Brown, R.E.5
  • 8
    • 4043171462 scopus 로고    scopus 로고
    • Upstream and downstream of mTOR
    • N. Hay, and N. Sonenberg Upstream and downstream of mTOR Genes Dev 18 16 Aug 15 2004 1926 1945
    • (2004) Genes Dev , vol.18 , Issue.16 , pp. 1926-1945
    • Hay, N.1    Sonenberg, N.2
  • 9
    • 4143098350 scopus 로고    scopus 로고
    • Human papillomavirus 16 E6 oncoprotein interferences with insulin signaling pathway by binding to tuberin
    • Z. Lu, X. Hu, Y. Li, L. Zheng, Y. Zhou, and H. Jiang Human papillomavirus 16 E6 oncoprotein interferences with insulin signaling pathway by binding to tuberin J Biol Chem 279 34 Aug 20 2004 35664 35670
    • (2004) J Biol Chem , vol.279 , Issue.34 , pp. 35664-35670
    • Lu, Z.1    Hu, X.2    Li, Y.3    Zheng, L.4    Zhou, Y.5    Jiang, H.6
  • 10
    • 0035312747 scopus 로고    scopus 로고
    • Regulation of translation initiation by FRAP/mTOR
    • A.C. Gingras, B. Raught, and N. Sonenberg Regulation of translation initiation by FRAP/mTOR Genes Dev 15 7 Apr 1 2001 807 826
    • (2001) Genes Dev , vol.15 , Issue.7 , pp. 807-826
    • Gingras, A.C.1    Raught, B.2    Sonenberg, N.3
  • 11
    • 84860363833 scopus 로고    scopus 로고
    • MTOR as a molecular target in HPV-associated oral and cervical squamous carcinomas
    • A.A. Molinolo, C. Marsh, M. El Dinali, N. Gangane, K. Jennison, and S. Hewitt mTOR as a molecular target in HPV-associated oral and cervical squamous carcinomas Clin Cancer Res 18 9 May 1 2012 2558 2568
    • (2012) Clin Cancer Res , vol.18 , Issue.9 , pp. 2558-2568
    • Molinolo, A.A.1    Marsh, C.2    El Dinali, M.3    Gangane, N.4    Jennison, K.5    Hewitt, S.6
  • 12
    • 34249779568 scopus 로고    scopus 로고
    • Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
    • G. Hudes, M. Carducci, P. Tomczak, J. Dutcher, R. Figlin, and A. Kapoor Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med 356 22 May 31 2007 2271 2281
    • (2007) N Engl J Med , vol.356 , Issue.22 , pp. 2271-2281
    • Hudes, G.1    Carducci, M.2    Tomczak, P.3    Dutcher, J.4    Figlin, R.5    Kapoor, A.6
  • 13
    • 48649107474 scopus 로고    scopus 로고
    • Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial
    • R.J. Motzer, B. Escudier, S. Oudard, T.E. Hutson, C. Porta, and S. Bracarda Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Lancet 372 9637 Aug 9 2008 449 456
    • (2008) Lancet , vol.372 , Issue.9637 , pp. 449-456
    • Motzer, R.J.1    Escudier, B.2    Oudard, S.3    Hutson, T.E.4    Porta, C.5    Bracarda, S.6
  • 14
    • 68949102180 scopus 로고    scopus 로고
    • Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma
    • G. Hess, R. Herbrecht, J. Romaguera, G. Verhoef, M. Crump, and C. Gisselbrecht Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma J Clin Oncol 27 23 Aug 10 2009 3822 3829
    • (2009) J Clin Oncol , vol.27 , Issue.23 , pp. 3822-3829
    • Hess, G.1    Herbrecht, R.2    Romaguera, J.3    Verhoef, G.4    Crump, M.5    Gisselbrecht, C.6
  • 16
    • 57849117384 scopus 로고    scopus 로고
    • New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
    • E.A. Eisenhauer, P. Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent, and R. Ford New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2 Jan 2009 228 247
    • (2009) Eur J Cancer , vol.45 , Issue.2 , pp. 228-247
    • Eisenhauer, E.A.1    Therasse, P.2    Bogaerts, J.3    Schwartz, L.H.4    Sargent, D.5    Ford, R.6
  • 17
    • 0024536437 scopus 로고
    • Optimal two-stage designs for phase II clinical trials
    • R. Simon Optimal two-stage designs for phase II clinical trials Control Clin Trials 10 1 Mar 1989 1 10
    • (1989) Control Clin Trials , vol.10 , Issue.1 , pp. 1-10
    • Simon, R.1
  • 18
    • 33748288069 scopus 로고    scopus 로고
    • Metaphase and array comparative genomic hybridization: Unique copy number changes and gene amplification of medulloblastomas in South America
    • M. Yoshimoto, J. Bayani, P.A. Nuin, N.S. Silva, S. Cavalheiro, and J.N. Stavale Metaphase and array comparative genomic hybridization: unique copy number changes and gene amplification of medulloblastomas in South America Cancer Genet Cytogenet 170 1 Oct 1 2006 40 47
    • (2006) Cancer Genet Cytogenet , vol.170 , Issue.1 , pp. 40-47
    • Yoshimoto, M.1    Bayani, J.2    Nuin, P.A.3    Silva, N.S.4    Cavalheiro, S.5    Stavale, J.N.6
  • 19
    • 64549158092 scopus 로고    scopus 로고
    • Overexpression of PIK3CA is associated with lymph node metastasis in esophageal squamous cell carcinoma
    • I. Akagi, M. Miyashita, H. Makino, T. Nomura, N. Hagiwara, and K. Takahashi Overexpression of PIK3CA is associated with lymph node metastasis in esophageal squamous cell carcinoma Int J Oncol 34 3 Mar 2009 767 775
    • (2009) Int J Oncol , vol.34 , Issue.3 , pp. 767-775
    • Akagi, I.1    Miyashita, M.2    Makino, H.3    Nomura, T.4    Hagiwara, N.5    Takahashi, K.6
  • 20
    • 34548299547 scopus 로고    scopus 로고
    • FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome
    • M. Yoshimoto, I.W. Cunha, R.A. Coudry, F.P. Fonseca, C.H. Torres, and F.A. Soares FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome Br J Cancer 97 5 Sep 3 2007 678 685
    • (2007) Br J Cancer , vol.97 , Issue.5 , pp. 678-685
    • Yoshimoto, M.1    Cunha, I.W.2    Coudry, R.A.3    Fonseca, F.P.4    Torres, C.H.5    Soares, F.A.6
  • 21
    • 61549141361 scopus 로고    scopus 로고
    • Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study
    • B.J. Monk, M.W. Sill, R.A. Burger, H.J. Gray, T.E. Buekers, and L.D. Roman Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study J Clin Oncol 27 7 Mar 1 2009 1069 1074
    • (2009) J Clin Oncol , vol.27 , Issue.7 , pp. 1069-1074
    • Monk, B.J.1    Sill, M.W.2    Burger, R.A.3    Gray, H.J.4    Buekers, T.E.5    Roman, L.D.6
  • 22
    • 84861690519 scopus 로고    scopus 로고
    • Biologic rationale and clinical activity of mTOR inhibitors in gynecological cancer
    • I. Diaz-Padilla, I. Duran, B.A. Clarke, and A.M. Oza Biologic rationale and clinical activity of mTOR inhibitors in gynecological cancer Cancer Treat Rev 38 6 Oct 2012 767 775
    • (2012) Cancer Treat Rev , vol.38 , Issue.6 , pp. 767-775
    • Diaz-Padilla, I.1    Duran, I.2    Clarke, B.A.3    Oza, A.M.4
  • 23
    • 77955874058 scopus 로고    scopus 로고
    • Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer
    • B.J. Monk, L. Mas Lopez, J.J. Zarba, A. Oaknin, C. Tarpin, and W. Termrungruanglert Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer J Clin Oncol 28 22 Aug 1 2010 3562 3569
    • (2010) J Clin Oncol , vol.28 , Issue.22 , pp. 3562-3569
    • Monk, B.J.1    Mas Lopez, L.2    Zarba, J.J.3    Oaknin, A.4    Tarpin, C.5    Termrungruanglert, W.6
  • 24
  • 25
    • 70749142744 scopus 로고    scopus 로고
    • Adenocarcinoma: A unique cervical cancer
    • L.T. Gien, M.C. Beauchemin, and G. Thomas Adenocarcinoma: a unique cervical cancer Gynecol Oncol 116 1 Jan 2010 140 146
    • (2010) Gynecol Oncol , vol.116 , Issue.1 , pp. 140-146
    • Gien, L.T.1    Beauchemin, M.C.2    Thomas, G.3
  • 26
    • 84863393080 scopus 로고    scopus 로고
    • Intratumor heterogeneity and branched evolution revealed by multiregion sequencing
    • M. Gerlinger, A.J. Rowan, S. Horswell, J. Larkin, D. Endesfelder, and E. Gronroos Intratumor heterogeneity and branched evolution revealed by multiregion sequencing N Engl J Med 366 10 Mar 8 2012 883 892
    • (2012) N Engl J Med , vol.366 , Issue.10 , pp. 883-892
    • Gerlinger, M.1    Rowan, A.J.2    Horswell, S.3    Larkin, J.4    Endesfelder, D.5    Gronroos, E.6
  • 27
    • 84880261973 scopus 로고    scopus 로고
    • Intratumoral heterogeneity in high-grade serous cancers: Defining evolution of the somatic mutational landscape across spatially and temporally selected samples
    • J.N. McAlpine, A. Bashashati, G. Ha, J. Rosner, J. Ding, and K. Shumansky Intratumoral heterogeneity in high-grade serous cancers: defining evolution of the somatic mutational landscape across spatially and temporally selected samples IGCS 2012:Plenary Session 2012
    • (2012) IGCS 2012:Plenary Session
    • McAlpine, J.N.1    Bashashati, A.2    Ha, G.3    Rosner, J.4    Ding, J.5    Shumansky, K.6
  • 28
    • 70349969478 scopus 로고    scopus 로고
    • Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution
    • S.P. Shah, R.D. Morin, J. Khattra, L. Prentice, T. Pugh, and A. Burleigh Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution Nature 461 7265 Oct 8 2009 809 813
    • (2009) Nature , vol.461 , Issue.7265 , pp. 809-813
    • Shah, S.P.1    Morin, R.D.2    Khattra, J.3    Prentice, L.4    Pugh, T.5    Burleigh, A.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.